Senate Confirms Dr. Erica Schwartz as CDC Director in 51-44 Vote Amid Agency Turmoil
The U.S. Senate confirmed Dr. Erica Schwartz as CDC director with a 51-44 vote, making her the 22nd leader of the agency and the first confirmed CDC director in nearly a year amid significant workforce reductions and leadership challenges.
What happened
The U.S. Senate confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention (CDC) on Wednesday, August 5, 2026, with a confirmation vote of 51-44 in favor. At 54 years old, Dr. Schwartz becomes the 22nd leader of the CDC, which is based in Atlanta and charged with protecting Americans from preventable health threats. She was nominated in April 2026 and will be the agency's first confirmed director in nearly a year.
Dr. Schwartz's confirmation comes after a contentious confirmation process. Her nomination appeared to be on shaky ground following a hearing before the Senate Health, Education, Labor and Pensions Committee last month. During that hearing, committee chairman Sen. Bill Cassidy, R-La., and others questioned whether she would be willing to stand up to Republican President Donald Trump's health secretary, Robert F. Kennedy Jr., if he ordered the CDC to do something unsupported by science and good public health practice.
However, weeks later, Cassidy said he had spoken with Schwartz after that hearing and with others who knew her, and said he had gained confidence in her. The Senate proceeded with the confirmation vote, resulting in a 51-44 margin.
Dr. Schwartz's resume includes medical and law degrees, a stint as deputy surgeon general, and a leadership position at the U.S. Coast Guard. Her background has been cited by public health experts as a reason for cautious optimism about her nomination.
Why it matters
The confirmation of Dr. Schwartz represents a significant development for public health leadership at a time when the CDC has experienced substantial turmoil. According to AP News, the CDC has lost 3,000-plus employees since Trump returned to office last year, representing more than one-quarter of its workforce. Morale has plummeted as a succession of mostly temporary leaders has come and gone.
The front office has been staffed by political appointees with little or no training in medicine or public health. This staffing issue has raised concerns among public health officials about the agency's ability to effectively carry out its mission.
Dr. Schwartz's confirmation comes after a pattern of multiple nominations and confirmations in recent months, suggesting ongoing efforts to fill key positions at the agency despite the broader context of personnel reductions. The relatively narrow margin of 51-44 in the confirmation vote reflects the partisan nature of such appointments in the current political environment.
The National Public Health Coalition, an organization of former and current CDC workers, issued a statement Wednesday emphasizing that "Dr. Schwartz needs to prove that her leadership will serve science and not the whims of politicians. CDC needs a Director who will protect public health workers, defend evidence-based guidance, and refuse any directive that would undermine public safety."
Dr. Georges Benjamin of the American Public Health Association also weighed in, stating that "With all the turmoil of the past two years, the CDC desperately needs stability, experienced leadership and a steadfast commitment to science."
These statements highlight the expectations placed on Dr. Schwartz as she takes on this critical role. Her ability to navigate the challenges facing the agency — including rebuilding workforce capacity, maintaining scientific integrity, and ensuring effective public health operations — will be closely watched by public health officials, policymakers, and the American public.
The confirmation also marks a continuation of the administration's efforts to appoint leadership across federal agencies. Dr. Schwartz was the third Trump nominee for CDC director in the past 18 months. The first nominee, Dr. David Weldon, a former Florida congressman, had his Senate hearing canceled an hour before it was to begin in March 2025. He said at the time that he had been told not enough senators were willing to vote for him.
The second nominee, Susan Monarez, who had been serving as the CDC's acting director, was confirmed by the Senate but ousted from the job in less than a month. Trump administration officials said she was not aligned with the president's agenda, so they terminated her. Since then, there have been a series of HHS officials as acting CDC directors.
The CDC position was one of several leadership vacancies among federal health agencies, including the U.S. surgeon general and the commissioner of the Food and Drug Administration. These vacancies underscore the broader challenges facing the federal health workforce during this period.
What to watch
Key developments to monitor include Dr. Schwartz's priorities for rebuilding CDC capacity following the significant workforce reductions, her approach to public health initiatives, and how she will address the agency's staffing challenges. The confirmation also marks a continuation of the administration's efforts to appoint leadership across federal agencies.
The broader context of 3,000-plus employees lost since Trump returned to office last year suggests that Dr. Schwartz will face immediate challenges in stabilizing the agency's workforce and maintaining its operational capacity. Her ability to navigate these challenges while implementing her vision for CDC operations will be closely watched by public health officials, policymakers, and the American public.
The confirmation vote of 51-44 indicates that while there was support for Dr. Schwartz's appointment, there was also significant opposition, suggesting that her nomination has been subject to considerable debate in the Senate. The nature of this debate and the issues raised during the confirmation process will likely continue to influence discussions about public health policy and CDC operations.
As Dr. Schwartz assumes her role, stakeholders will be watching to see whether she can deliver on the expectations set by public health organizations and whether she can maintain scientific independence while working within the administration's broader policy framework. The coming months will be critical in determining whether she can stabilize the agency and restore confidence in its leadership.
By the numbers
- Confirmation vote: 51-44
- Age of Dr. Schwartz: 54
- CDC leadership number: 22nd
- Employees lost: 3,000+
- Time since last confirmed director: Nearly a year
- Nomination date: April 2026
- Previous nominee hearing cancellation: March 2025
- Acting director tenure before Schwartz: Less than a month
Source snapshot
